Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles

Nosengo, 2016, Can you teach old drugs new tricks?, Nature, 534, 314, 10.1038/534314a Dudley, 2011, Exploiting drug-disease relationships for computational drug repositioning, Brief Bioinform, 12, 303, 10.1093/bib/bbr013 Weinstein, 1997, An information-intensive approach to the molecular pharmacology of cancer, Science, 275, 343, 10.1126/science.275.5298.343 Hughes, 2004, Old drugs, new tricks: using genetically sensitized yeast to reveal drug targets, Cell, 116, 5, 10.1016/S0092-8674(03)01070-5 Booij, 2019, In vitro 3d phenotypic drug screen identifies celastrol as an effective in vivo inhibitor of polycystic kidney disease, J Mol Cell Biol Mullen, 2016, An integrated data driven approach to drug repositioning using gene-disease associations, PLoS ONE, 11, 10.1371/journal.pone.0155811 Keiser, 2009, Predicting new molecular targets for known drugs, Nature, 462, 175, 10.1038/nature08506 Lamb, 2006, The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease, Science, 313, 1929, 10.1126/science.1132939 Readhead, 2018, Expression-based drug screening of neural progenitor cells from individuals with schizophrenia, Nat Commun, 9, 4412, 10.1038/s41467-018-06515-4 Subramanian, 2017, A next generation connectivity map: L1000 platform and the first 1,000,000 profiles, Cell, 171, 10.1016/j.cell.2017.10.049 Lanktree, 2018, Prevalence estimates of polycystic kidney and liver disease by population sequencing, J Am Soc Nephrol, 29, 2593, 10.1681/ASN.2018050493 Willey, 2017, Prevalence of autosomal dominant polycystic kidney disease in the European Union, Nephrol Dial Transplant, 32, 1356 Audrezet, 2012, Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients, Hum Mutat, 33, 1239, 10.1002/humu.22103 Spithoven, 2014, Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival–an analysis of data from the ERA-EDTA registry, Nephrol Dial Transplant, 29, 10.1093/ndt/gfu017 Menezes, 2016, Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease, EBioMedicine, 5, 183, 10.1016/j.ebiom.2016.01.027 Harris, 2014, Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease, J Clin Invest, 124, 2315, 10.1172/JCI72272 Serra, 2010, Sirolimus and kidney growth in autosomal dominant polycystic kidney disease, N Engl J Med, 363, 820, 10.1056/NEJMoa0907419 Walz, 2010, Everolimus in patients with autosomal dominant polycystic kidney disease, N Engl J Med, 363, 830, 10.1056/NEJMoa1003491 Caroli, 2013, Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial, Lancet, 382, 1485, 10.1016/S0140-6736(13)61407-5 Torres, 2012, Tolvaptan in patients with autosomal dominant polycystic kidney disease, N Engl J Med, 367, 2407, 10.1056/NEJMoa1205511 Verbist, 2015, Using transcriptomics to guide lead optimization in drug discovery projects: lessons learned from the QSTAR project, Drug Discov Today, 20, 505, 10.1016/j.drudis.2014.12.014 Dixit, 2016, RNA-seq analysis of hippocampal tissues reveals novel candidate genes for drug refractory epilepsy in patients with MTLE-HS, Genomics, 107, 178, 10.1016/j.ygeno.2016.04.001 Novalic, 2012, Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease, J Am Soc Nephrol, 23, 842, 10.1681/ASN.2011040340 Leonhard, 2016, Inhibition of activin signaling slows progression of polycystic kidney disease, J Am Soc Nephrol, 27, 3589, 10.1681/ASN.2015030287 Happe, 2009, Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways, Hum Mol Genet, 18, 2532, 10.1093/hmg/ddp190 Leonhard, 2011, Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model, Am J Physiol Renal Physiol, 300, F1193, 10.1152/ajprenal.00419.2010 Kim, 2013, TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions, Genome Biol, 14, R36, 10.1186/gb-2013-14-4-r36 Ritchie, 2015, limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res, 43, e47, 10.1093/nar/gkv007 Song, 2009, Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks, Hum Mol Genet, 18, 2328, 10.1093/hmg/ddp165 Backes, 2007, GeneTrail–advanced gene set enrichment analysis, Nucleic Acids Res, 35, W186, 10.1093/nar/gkm323 Papadatos, 2015, Activity, assay and target data curation and quality in the chembl database, J Comput Aided Mol Des, 29, 885, 10.1007/s10822-015-9860-5 Kersey, 2010, Ensembl genomes: extending Ensembl across the taxonomic space, Nucleic Acids Res, 38, D563, 10.1093/nar/gkp871 Gaulton, 2012, ChEMBL: a large-scale bioactivity database for drug discovery, Nucleic Acids Res, 40, D1100, 10.1093/nar/gkr777 Booij, 2017, High-Throughput phenotypic screening of kinase inhibitors to identify drug targets for polycystic kidney disease, SLAS Discov, 22, 974, 10.1177/2472555217716056 Leonhard, 2016, Variable Cyst development in autosomal dominant polycystic kidney disease: the biologic context, J Am Soc Nephrol, 27, 3530, 10.1681/ASN.2016040425 Buchholz, 2011, Formation of cysts by principal-like MDCK cells depends on the synergy of cAMP- and ATP-mediated fluid secretion, J Mol Med (Berl), 89, 251, 10.1007/s00109-010-0715-1 Chang, 2011, Inhibition of the P2 × 7 receptor reduces cystogenesis in PKD, J Am Soc Nephrol, 22, 1696, 10.1681/ASN.2010070728 Liu, 2011, Suramin inhibits renal fibrosis in chronic kidney disease, J Am Soc Nephrol, 22, 1064, 10.1681/ASN.2010090956 Flaig, 2016, Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor gamma agonists, J Transl Int Med, 4, 118, 10.1515/jtim-2016-0028 Blazer-Yost, 2010, Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease, PPAR Res, 2010, 10.1155/2010/274376 Dai, 2010, Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats, Clin Sci (Lond), 119, 323, 10.1042/CS20100113 Fan, 2013, Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts, J Am Soc Nephrol, 24, 2010, 10.1681/ASN.2013020176 Higashihara, 2008, The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD, Nephrol Dial Transplant, 23, 2847, 10.1093/ndt/gfn144 Tao, 2005, Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease, J Am Soc Nephrol, 16, 46, 10.1681/ASN.2004080660 Torres, 2017, Tolvaptan in later-stage autosomal dominant polycystic kidney disease, N Engl J Med, 377, 1930, 10.1056/NEJMoa1710030 Rowe, 2013, Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy, Nat Med, 19, 488, 10.1038/nm.3092 Yamaguchi, 2003, Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys, Kidney Int, 63, 1983, 10.1046/j.1523-1755.2003.00023.x Shillingford, 2006, The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease, Proc Natl Acad Sci U S A, 103, 5466, 10.1073/pnas.0509694103 Cassini, 2018, Mcp1 promotes macrophage-dependent cyst expansion in autosomal dominant polycystic kidney disease, J Am Soc Nephrol, 29, 2471, 10.1681/ASN.2018050518 Yang, 2018, Interactions between macrophages and cyst-lining epithelial cells promote kidney cyst growth in Pkd1-deficient mice, J Am Soc Nephrol, 29, 2310, 10.1681/ASN.2018010074 Malas, 2017, Meta-analysis of polycystic kidney disease expression profiles defines strong involvement of injury repair processes, Am J Physiol Renal Physiol, 312, F806, 10.1152/ajprenal.00653.2016 Hu, 2013, High-resolution view of compound promiscuity, F1000Res, 2, 144, 10.12688/f1000research.2-144.v1 Flanagan, 2012, Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3, PLoS ONE, 7, e43965, 10.1371/journal.pone.0043965 Aziz, 1994, Coordinate regulation of 11 beta-HSD and Ke 6 genes in cpk mouse: implications for steroid metabolic defect in PKD, Am J Physiol, 267, F791 Lakhia, 2018, PPARalpha agonist fenofibrate enhances fatty acid beta-oxidation and attenuates polycystic kidney and liver disease in mice, Am J Physiol Renal Physiol, 314, F122, 10.1152/ajprenal.00352.2017 Srivastava, 2016, Effect of a smac mimetic (TL32711, birinapant) on the apoptotic program and apoptosis biomarkers examined with validated multiplex immunoassays fit for clinical use, Clin Cancer Res, 22, 1000, 10.1158/1078-0432.CCR-14-3156 de Almeida, 2016, Transcriptome analysis reveals manifold mechanisms of cyst development in ADPKD, Hum Genomics, 10, 37, 10.1186/s40246-016-0095-x Pandey, 2011, Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease, BMC Syst Biol, 5, 56, 10.1186/1752-0509-5-56 Tesar, 2017, Bosutinib versus placebo for autosomal dominant polycystic kidney disease, J Am Soc Nephrol, 28, 3404, 10.1681/ASN.2016111232 Zhou, 2015, Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD, Hum Mol Genet, 24, 3982, 10.1093/hmg/ddv136 Weimbs, 2018, Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease, Clin Kidney J, 11, i27, 10.1093/ckj/sfy089 Seeger-Nukpezah, 2013, Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease, Proc Natl Acad Sci U S A, 110, 12786, 10.1073/pnas.1301904110 Shillingford, 2010, Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1, J Am Soc Nephrol, 21, 489, 10.1681/ASN.2009040421 Hwang, 2016, Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease, J Am Soc Nephrol, 27, 1861, 10.1681/ASN.2015060648 Lenselink, 2017, Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set, J Cheminform, 9, 45, 10.1186/s13321-017-0232-0